Background Although the number of newly detected leprosy cases has decreased globally, a quarter of a million new cases are detected annually and eradication remains far away. Current options for leprosy prevention are contact tracing and BCG vaccination of infants. Future options may include chemoprophylaxis and early diagnosis of subclinical infections. This study compared the predicted trends in leprosy case detection of future intervention strategies. Methods Seven leprosy intervention scenarios were investigated with a microsimulation model (SIMCOLEP) to predict future leprosy trends. The baseline scenario consisted of passive case detection, multidrug therapy, contact tracing, and BCG vaccination of infants. The other six scenarios were modifications of the baseline, as follows: no contact tracing; with chemoprophylaxis; with early diagnosis of subclinical infections; replacement of the BCG vaccine with a new tuberculosis vaccine ineffective against Mycobacterium leprae (“no BCG”); no BCG with chemoprophylaxis; and no BCG with early diagnosis. Findings Without contact tracing, the model predicted an initial drop in the new case detection rate due to a delay in detecting clinical cases among contacts. Eventually, this scenario would lead to new case detection rates higher than the baseline program. Both chemoprophylaxis and early diagnosis would prevent new cases due to a reduction of the infectious period of subclinical cases by detection and cure of these cases. Also, replacing BCG would increase the new case detection rate of leprosy, but this effect could be offset with either chemoprophylaxis or early diagnosis. Conclusions This study showed that the leprosy incidence would be reduced substantially by good BCG vaccine coverage and the combined strategies of contact tracing, early diagnosis, and treatment of infection and/or chemoprophylaxis among household contacts. To effectively interrupt the transmission of M. leprae, it is crucial to continue developing immuno- and chemoprophylaxis strategies and an effective test for diagnosing subclinical infections.
Moet FJ, Pahan D, Oskam L, Richardus JH (2008) Effectiveness of single dose rifampicin in preventing leprosy in close contacts of patients with newly diagnosed leprosy: cluster randomised controlled trial. Bmj 336: 761–764. doi: 10.1136/bmj.39500.885752.BE
[3]
Reveiz L, Buendia JA, Tellez D (2009) Chemoprophylaxis in contacts of patients with leprosy: systematic review and meta-analysis. Rev Panam Salud Publica 26: 341–349. doi: 10.1590/S1020-49892009001000009
[4]
Geluk A, Spencer JS, Bobosha K, Pessolani MC, Pereira GM, et al. (2009) From genome-based in silico predictions to ex vivo verification of leprosy diagnosis. Clin Vaccine Immunol 16: 352–359. doi: 10.1128/CVI.00414-08
[5]
Merle CS, Cunha SS, Rodrigues LC (2010) BCG vaccination and leprosy protection: review of current evidence and status of BCG in leprosy control. Expert Rev Vaccines 9: 209–222. doi: 10.1586/erv.09.161
[6]
Kaufmann SH, Hussey G, Lambert PH (2010) New vaccines for tuberculosis. Lancet 375: 2110–2119. doi: 10.1016/S0140-6736(10)60393-5
[7]
Brennan MJ, Fruth U, Milstien J, Tiernan R, de Andrade Nishioka S, et al. (2007) Development of new tuberculosis vaccines: a global perspective on regulatory issues. PLoS Med 4: e252. doi: 10.1371/journal.pmed.0040252
[8]
Richardus JH, Saunderson P, Smith C (2011) Will new tuberculosis vaccines provide protection against leprosy? Int J Tuberc Lung Dis 15: 143.
[9]
Fischer E, De Vlas S, Meima A, Habbema D, Richardus J (2010) Different mechanisms for heterogeneity in leprosy susceptibility can explain disease clustering within households. PLoS One 5: e14061. doi: 10.1371/journal.pone.0014061
[10]
Moet FJ, Oskam L, Faber R, Pahan D, Richardus JH (2004) A study on transmission and a trial of chemoprophylaxis in contacts of leprosy patients: design, methodology and recruitment findings of COLEP. Lepr Rev 75: 376–388.
[11]
Moet FJ, Pahan D, Schuring RP, Oskam L, Richardus JH (2006) Physical distance, genetic relationship, age, and leprosy classification are independent risk factors for leprosy in contacts of patients with leprosy. J Infect Dis 193: 346–353. doi: 10.1086/499278
[12]
Fischer E, Pahan D, Chowdhury S, Oskam L, Richardus J (2008) The spatial distribution of leprosy in four villages in Bangladesh: an observational study. BMC Infect Dis 8: 125. doi: 10.1186/1471-2334-8-125
[13]
Moet FJ, Schuring RP, Pahan D, Oskam L, Richardus JH (2008) The prevalence of previously undiagnosed leprosy in the general population of northwest bangladesh. PLoS Negl Trop Dis 2: e198. doi: 10.1371/journal.pntd.0000198
[14]
Fine PE (1982) Leprosy: the epidemiology of a slow bacterium. Epidemiol Rev 4: 161–188.
[15]
Noordeen S (1985) The epidemiology of leprosy. In: Hastings R, editor. Leprosy. Edinburgh: Churchill Livingstone.
[16]
Meima A, Smith WC, van Oortmarssen GJ, Richardus JH, Habbema JD (2004) The future incidence of leprosy: a scenario analysis. Bull World Health Organ 82: 373–380.
[17]
Anonymous (2007) WHO/UNICEF review of national immunization coverage, 1980-2006. Geneva: World Health Organization.
[18]
Setia MS, Steinmaus C, Ho CS, Rutherford GW (2006) The role of BCG in prevention of leprosy: a meta-analysis. Lancet Infect Dis 6: 162–170. doi: 10.1016/S1473-3099(06)70412-1
[19]
Schuring RP, Moet FJ, Pahan D, Richardus JH, Oskam L (2006) Association between anti-pGL-I IgM and clinical and demographic parameters in leprosy. Lepr Rev 77: 343–355.
[20]
Gillis T, Vissa V, Matsuoka M, Young S, Richardus JH, et al. (2009) Characterisation of short tandem repeats for genotyping Mycobacterium leprae. Lepr Rev 80: 250–260.
[21]
Hall BG, Salipante SJ (2010) Molecular epidemiology of Mycobacterium leprae as determined by structure-neighbor clustering. J Clin Microbiol 48: 1997–2008. doi: 10.1128/JCM.00149-10
[22]
Schuring RP, Richardus JH, Pahan D, Oskam L (2009) Protective effect of the combination BCG vaccination and rifampicin prophylaxis in leprosy prevention. Vaccine 27: 7125–7128. doi: 10.1016/j.vaccine.2009.09.054
